Key clinical point: Female sex, tyrosine kinase inhibitor (TKI) therapy-related symptoms, older age at diagnosis, younger age at the time of the study, and low maternal education were associated with worse health-related quality of life (HRQoL) in children with chronic-phase chronic myeloid leukemia (CML-CP) receiving TKI therapy.
Major finding: Worse HRQoL was observed in children with symptoms ( P < .001), children with mothers having low educational qualifications ( P = .005), children at a younger age at the time of the study ( P = .008), children with older age at the time of diagnosis ( P = .007), and female children ( P = .038).
Study details: Findings are from a cross-sectional study of 240 respondents including children with CML-CP (age < 18 years at diagnosis) receiving TKI therapy and whose parents responded to a cross-sectional questionnaire.
Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no conflict of interests.
Source: Zheng F et al. J Cancer Res Clin Oncol. 2021(Oct 29). Doi: 10.1007/s00432-021-03832-y.